ANN ARBOR, Mich. —The Sunday, Aug. 5 and Monday, Aug. 6 editions of the Detroit Free Pressfeatured major stories on U-M’s role in research and care for people with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
The stories included information about a groundbreaking clinical trial occurring at Emory University involving stem cells, and being led by Eva Feldman, M.D., Ph.D., a U-M neurologist and ALS specialist.
Read the stories here:
The article mentions that there is an effort under way to open the stem cell trial to patients at U-M. While we are currently seeking approvals from our Institutional Review Board and the U.S. Food and Drug Administration to do so, the trial is not open at this time.
When and if we receive all needed approvals, we will post information about the trial, and the types of patients who might be eligible to enroll, atwww.umclinicalstudies.org, the site that lists current clinical trials at U-M that need participants.
Please bookmark that site and visit it again in coming weeks; search for “amyotrophic” to find all studies open to ALS patients.
If you or a loved one are affected by ALS, please visit our ALS clinic website for more information about treatment options offered at U-M.
For more information on the trial, please visit this page on the website of its sponsor, NeuralStem Inc.
For information on research results published this past April by a team co-led by Feldman, please read this article: http://www.uofmhealth.org/news/stem-cell-als-0409
To learn more about Feldman’s research, visit www.pnrd.umich.edu
For more information on stem cell research at U-M in general, visitwww.umich.edu/stemcell